0000886163-20-000027.txt : 20200227
0000886163-20-000027.hdr.sgml : 20200227
20200227203514
ACCESSION NUMBER: 0000886163-20-000027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200227
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FOEHR MATTHEW W
CENTRAL INDEX KEY: 0001237556
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 20665163
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES RD #200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-27
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001237556
FOEHR MATTHEW W
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO
CA
92121
0
1
0
0
President and COO
Common Stock
2020-02-27
4
M
0
7225
14.47
A
160968
D
Common Stock
2020-02-27
4
S
0
7225
110.0
D
153743
D
Common Stock
2020-02-27
4
M
0
1706
21.92
A
155449
D
Employee Stock Option (right to buy)
14.47
2020-02-27
2020-02-27
4
M
0
7225
0.0
D
2022-02-09
Common Stock
7225
7225
D
Employee Stock Option (right to buy)
21.92
2020-02-27
2020-02-27
4
M
0
1706
0.0
D
2023-02-15
Common Stock
1706
66625
D
The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 15, 2019, in accordance with Rule 10b5-1.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
By: Charles S. Berkman For: Matthew W. Foehr
2020-02-27